

REFERENCES

- Abdou, H.M. & Mohamed, N.A.. (2016). Centella asiatica ameliorates diabetic complications and oxidative stress in streptozotocin-induced diabetes mellitus in male rats. *Int J Pharm Sci*, 36, pp.S61-S70.
- Ahmed, S. A., & Hamed, M. A. (2015). Kidney injury molecule-1 as a predicting factor for inflamed kidney, diabetic and diabetic nephropathy Egyptian patients. *J Diabetes Metab Disord*, 14(1).
- Ali, O. (2013). Genetics of type 2 diabetes. *World J Diabetes*, 4(4), 114–123.
- Alsaraj, F. (2015). Pathogenesis of Type 2 Diabetes Mellitus. *Treatment of Type 2 Diabetes*.
- American Diabetes Association. (2003). Diabetic Nephropathy. *Diabetes Care*, 26 (Supplement 1). s94.
- American Diabetes Association. (2010). Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, 33(Suppl 1), S62–S69.
- American Diabetes Association. (2017). 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018. *Diabetes Care*, 41(Supplement 1), pp.S73-S85.
- Amin, S., Abdel Latif, N. and Rashed, L. (2017). Impact of Blocking Renin Angiotensin Aldosterone Axis in Acute Kidney Injury. *Int Ann Med*, 1(5).
- Arauz-Pacheco, C., Parrott, M. A., & Raskin, P. (2002). The Treatment of Hypertension in Adult Patients With Diabetes. *Diabetes Care*, 25(1), 134-147.
- Bailly, V., Zhang, Z., Meier, W., Cate, R., Sanicola, M., & Bonventre, J. V. (2002). Shedding of Kidney Injury Molecule-1, a Putative Adhesion Protein Involved in Renal Regeneration. *Journal of Biological Chemistry*, 277(42), 39739–39748.
- Bonventre, J. V. (2009). Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more. *Nephrol Dial Transplant*, 24(11), 3265-3268.
- Bonventre J. V. (2014). Kidney injury molecule-1: a translational journey. *Trans Am Clin Climatol Assoc*, 125, 293-9; discussion 299.
- Cade, W. T. (2008). Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. *Phys Ther*, 88(11), 1322–1335.
- Campbell, K. N., Raij, L., & Mundel, P. (2011). Role of Angiotensin II in the Development of Nephropathy and Podocytopathy of Diabetes. *Curr Diabetes Rev*, 7(1), 3-7.

- Cao, Z. and Cooper, M. (2011). Pathogenesis of diabetic nephropathy. *J Diabetes Investig*, 2(4), pp.243-247.
- Chawla, T. (2010). Role of the renin angiotensin system in diabetic nephropathy. *World J Diabetes*, 1(5), p.141.
- Diagnosis and Classification of Diabetes Mellitus. (2011). *Diabetes Care*, 35(Supplement_1), pp.S64-S71.
- Duran-Salgado, M. (2014). Diabetic nephropathy and inflammation. *World J Diabetes*, 5(3), p.393.
- Farrell, R. E. (2010). Rt-Pcr. *RNA Methodologies*, 385-448.
- Fahri, F. (2018). Effect of Centella asiatica (L.) Urban Extract on the Expression of eNOS mRNA in Kidney of Diabetic Nephropathy Wistar Rat Model. Universitas Gadjah Mada. Yogyakarta Indonesia.
- Fleige, S. and Pfaffl, M. (2006). RNA integrity and the effect on the real-time qRT-PCR performance. *Mol Aspects Med*, 27(2-3), pp.126-139.
- Foggensteiner, L., Mulroy, S., & Firth, J. (2001). Management of diabetic nephropathy. *J R Soc Med*, 94(5), 210–217.
- Fowler, M. J. (2011). Microvascular and Macrovascular Complications of Diabetes. *Clin Diabetes*, 29(3), 116-122.
- Gheibi, S., Kashfi, K. and Ghasemi, A. (2017). A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. *Biomed Pharmacother*, 95, pp.605-613.
- Ghasemi, A., Khalifi, S. and Jedi, S. (2014). Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (review). *Acta Physiol Hung*, 101(4), pp.408-420.
- Gohil, K., Patel, J. and Gajjar, A. (2010). Pharmacological review on Centella asiatica: A potential herbal cure-all. *Indian J Pharm Sci*, 72(5), p.546.
- Hansen, Klaus & Nyman, Ulf & Wagner Smitt, Ulla & Adersen, Anne & Gudiksen, Lene & Rajasekharan, Sreedharan & Pushpangadan, Palpu. (1995). In vitro screening of traditional medicines for anti-hypertensive effect based on inhibition of the angiotensin converting enzyme (ACE). *J Ethnopharmacol*. 48. 43-51.
- Hsu, F., Lin, F., Ou, H., Huang, S., & Wang, C. (2017). Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. *Kidney Blood Press Res*, 42(2), 358-368.
- Ichimura, T., Asseldonk, E. J. P. v., Humphreys, B. D., Gunaratnam, L., Duffield, J. S., & Bonventre, J. V. (2008). Kidney injury molecule-1 is a

phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. *J Clin Invest*, 118(5), 1657–1668.

Jovanovic, D., Dimitrijevic, J., Varagic, J., Jovovic, D., Starcevic, A., & Djukanovic, L. (1998) Effects of Captopril on Morphologic Changes in Kidney of Spontaneously Hypertensive Rats with Adriamycin Nephropathy. *Ren Fail*, 20:3, 451-458.

K Chauhan, P & P Pandey, I & Kumar Dhatwalia, Vinod. (200). Evaluation of the Anti-diabetic Effect of Ethanolic and Methanolic Extracts of Centella asiatica Leaves Extract on Alloxan Induced Diabetic Rats. *Adv Biol Res*. 4.

Kabir, A. U., Samad, M. B., D'Costa, N. M., Akhter, F., Ahmed, A., & Hannan, J. (2014). Anti-hyperglycemic activity of Centella asiatica is partly mediated by carbohydrase inhibition and glucose-fiber binding. *BMC Complement Altern Med*, 14(1). doi:10.1186/1472-6882-14-31

Kahn, S., Cooper, M. and Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet*, 383(9922), pp.1068-1083.

Kobori, H., Nangaku, M., Navar, L. G., & Nishiyama, A. (2007). The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. *Pharmacol Rev*, 59(3), 251-287.

Kumari, S., Harikumar, S. L., & Navis, S. (2014). Angiotensin Converting Enzyme (Ace) Inhibitors in the Treatment of Diabetic Nephropathy. *Int J Pharm Phytopharmacol Res*, 4(4), 211-217.

Leahy, J. L. (2005). Pathogenesis of Type 2 Diabetes Mellitus. *Arch Med Res*, 36(3), 197-209.

Lee, Y. H., Kim, Y. G., Lee, S. H., Moon, J. Y., Jeong, K. H., Lee, T. W., & Ihm, C. G. (2014). Clinicopathological role of kidney injury molecule-1 in immunoglobulin A nephropathy. *Kidney Res Clin Pract*, 33(3), 139-43.

Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993). The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. *N Engl J Med*, 329(20), 1456-1462.

Lim, Andy. (2014). Diabetic nephropathy – Complications and treatment. *Int J Nephrol Renovasc Dis*, 7. 361-81.

Mahler, R. J., & Adler, M. L. (1999). Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment. *J Clin Endocrinol Metab*, 84(4), 1165-1171.

Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & del Cañizo-Gómez, F. J. (2016). Update on the treatment of type 2 diabetes mellitus. *World J Diabetes*, 7(17), 354–395.

- Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012). Type 2 Diabetes Mellitus: A Review of Current Trends. *Oman Med J*, 27(4), 269–273.
- Pakdeechote, P., Bunbupha, S., Kukongviriyapan, U., Prachaney, P., Khrisanapant, W., & Kukongviriyapan, V. (2014). Asiatic Acid Alleviates Hemodynamic and Metabolic Alterations via Restoring eNOS/iNOS Expression, Oxidative Stress, and Inflammation in Diet-Induced Metabolic Syndrome Rats. *Nutrients*, 6(1), 355-370.
- Riset kesehatan dasar: Riskesdas, 2013*. (2013). Jakarta: Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan RI.
- Satirapoj, B. (2018). Tubulointerstitial Biomarkers for Diabetic Nephropathy. *J of Diabetes Res*, 2018, 1-6.
- Schena, F. (2005). Pathogenetic Mechanisms of Diabetic Nephropathy. *J Am Soc Nephrol*, 16(3_suppl_1), pp.S30-S33.
- Szkudelski, T. (2012). Streptozotocin–nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. *Exp Biol Med*, 237(5), 481–490.
- Tabish, S. A. (2007). Is Diabetes Becoming the Biggest Epidemic of the Twenty-first Century? *Int J Health Sci*, 1(2), V–VIII.
- Tekce, B. K., Tekce, H., Aktas, G., & Sit, M. (2014). Evaluation of the Urinary Kidney Injury Molecule-1 Levels in Patients With Diabetic Nephropathy. *Clin Invest Med*, 37(6), 377.
- Toth-Manikowski, S., & Atta, M. G. (2015). Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. *J Diabetes Res*, 2015, 1-16.
- Types of Diabetes. (2018). Retrieved October 16, 2018, from <https://www.diabetes.ca/about-diabetes/types-of-diabetes>
- Wang, Z., Liu, J., & Sun, W. (2013). Effects of asiaticoside on levels of podocyte cytoskeletal proteins and renal slit diaphragm proteins in adriamycin-induced rat nephropathy. *Life Sci*, 93(8), 352–358.
- Wiecek, A. (2003). Role of angiotensin II in the progression of diabetic nephropathy--therapeutic implications. *Nephrol Dial Transplant*, 18(90005), pp.16v-20.
- World Health Organization. (2018). Diabetes. [online] Available at: <http://www.who.int/mediacentre/factsheets/fs312/en/> [Accessed 29 Mar. 2018].
- World Health Organization. (2016). *Global report on diabetes*. World Health Organization.



- Xu, C., Wang, W., Xu, M., & Zhang, J. (2013). Asiatic acid ameliorates tubulointerstitial fibrosis in mice with ureteral obstruction. *Exp Ther Med*, 6(3), 731-736.
- Zainol, M., Abd-Hamid, A., Yusof, S., & Muse, R. (2003). Antioxidative activity and total phenolic compounds of leaf, root and petiole of four accessions of *Centella asiatica* (L.) Urban. *Food Chem*, 81(4), 575-581.
- Zhao, X., Zhang, Y., Li, L., Mann, D., Imig, J. D., Emmett, N., Jin, L. (2011). Glomerular Expression of Kidney Injury Molecule-1 and Podocytopenia in Diabetic Glomerulopathy. *Am J Nephrol*, 34(3), 268-280.